More on Health Practitioners

Por Pakes, Gary E.
Publicado em 1978

Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy

Por Horizon, Arash A, Joseph, Robert J, Liao, Qiming, Ross, Steven T, Pakes, Gary E
Publicado em 2011

Steady-State Pharmacokinetics, Cord Blood Concentrations, and Safety of Ritonavir-Boosted Fosamprenavir in Pregnancy

Por Cespedes, Michelle S., Castor, Delivette, Ford, Susan L., Lee, Doreen, Lou, Yu, Pakes, Gary E., Aberg, Judith A.
Publicado em 2013

Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-Infected Patients Enrolled in Two Phase III Clinical Trials

Por Moore, Katy H. P., Yuen, Geoffrey J., Hussey, Elizabeth K., Pakes, Gary E., Eron, Joseph J., Bartlett, John A.
Publicado em 1999

Predictive Value of Pharmacokinetics-Adjusted Phenotypic Susceptibility on Response to Ritonavir-Enhanced Protease Inhibitors (PIs) in Human Immunodeficiency Virus-Infected Subject...

Por Eron, Joseph J., Park, Jeong-Gun, Haubrich, Richard, Aweeka, Francesca, Bastow, Barbara, Pakes, Gary E., Yu, Song, Wu, Hulin, Richman, Douglas D.
Publicado em 2009

Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population

Por Rawlings, M Keith, Klein, Jennifer, Klingler, Edna P Toubes, Queen, Ejeanée, Rogers, Lauren, Yau, Linda H, Pappa, Keith A, Pakes, Gary E
Publicado em 2011

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens

Por Swindells, Susan, Cohen, Calvin J, Berger, Daniel S, Tashima, Karen T, Liao, Qiming, Pobiner, Bonnie F, Snidow, Jerry W, Pakes, Gary E, Hernandez, Jaime E
Publicado em 2005

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks

Por Squires, Kathleen E, Young, Benjamin, Santiago, Lizette, Dretler, Robin H, Walmsley, Sharon L, Zhao, Henry H, Pakes, Gary E, Ross, Lisa L, Shaefer, Mark S
Publicado no HIV AIDS (Auckl) (2017)

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT

Por Smith, Kimberly Y, Weinberg, Winkler G, DeJesus, Edwin, Fischl, Margaret A, Liao, Qiming, Ross, Lisa L, Pakes, Gary E, Pappa, Keith A, Lancaster, C Tracey
Publicado em 2008

Impact of Low Abundance HIV Variants on Response to Ritonavir-Boosted Atazanavir or Fosamprenavir Given Once Daily with Tenofovir/Emtricitabine in Antiretroviral-Naive HIV-Infected...

Por Ross, Lisa L., Weinberg, Winkler G., DeJesus, Edwin, Fischl, Margaret A., Horton, Joseph H., Pappa, Keith A., Lancaster, C. Tracey, Pakes, Gary E., Smith, Kimberly Y.
Publicado em 2010

Inflammatory Biomarker Changes and Their Correlation with Framingham Cardiovascular Risk and Lipid Changes in Antiretroviral-Naive HIV-Infected Patients Treated for 144 Weeks with...

Por Young, Benjamin, Squires, Kathleen E., Ross, Lisa L., Santiago, Lizette, Sloan, Louis M., Zhao, Henry H., Wine, Brian C., Pakes, Gary E., Margolis, David A., Shaefer, Mark S.
Publicado em 2013

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment

Por Keiser, Philip H, Sension, Michael G, DeJesus, Edwin, Rodriguez, Allan, Olliffe, Jeffrey F, Williams, Vanessa C, Wakeford, John H, Snidow, Jerry W, Shachoy-Clark, Anne D, Fleming, Julie W, Pakes, Gary E, Hernandez, Jaime E
Publicado em 2005